Reported about 9 hours ago
Structure Therapeutics Inc. (GPCR), a biopharmaceutical firm specializing in AI-driven therapies for metabolic conditions, is progressing with its obesity drug, aleniglipron, through two pivotal Phase 2b trials. Results are anticipated by the end of 2025, which could validate its innovative approach. Despite a significant net loss in Q2 2025, the company holds a strong cash reserve to fund research until 2027, while preparing for additional trials to enhance its product offerings in the obesity market.
Source: YAHOO